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TRANSPLANT ATION 
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OUR EXPERIENCE with cyclosporine for cadaveric renal transplantation be-
gan in late 1979. An article by CaIne et al. l 
had just been published that gave critics of our 
trial a lot of ammunition. Although the path-
finding report by Caine and his associates 
contained the good news that rejection of 
some cadaveric kidneys had been avoided with 
no drug other than cyclosporine, the bad news 
was that there had been a high patient mortal-
ity in these Cambridge trials, that none of the 
kidneys was providing normal function, and 
that nearly 10% of the recipients had devel-
oped Iymphomas. l 
MATERIALS AND METHODS 
In spite of these warning signs, a large-scale clinical 
trial of cadaveric renal transplantation was mounted; this 
is now 3'/2 years old (Table 1). Sixty-six patients were 
treated at the University of Colorado in a non·random· 
ized trial between December 1979 and September 1980. 
This was a learning period in which it was realized that 
cyclosporine should be used with steroids for optimum 
efficiency.2 However the exact formula for the prednisone 
interaction with cyclosporine had not yet been worked 
out. In addition, the dose manipulation of cyclosporine 
that was frequently necessitated by the nephrotoxicity of 
this drug had not yet been clarified. These subtleties of 
management were described later'" and were applied in 
the Pittsburgh series. 
RESULTS 
Phase I (1979-1980) 
The results in the Colorado trials were 
surprisingly good in spite of a learning curve 
effect (Table 2). Almost 80% of the primary 
cadaveric grafts were still functioning at the 
end of 1 year, as well as 60% of the cadaveric 
kidneys used for retransplantation. 
The I-year results have held up well. Now, 
with a median follow-up of about 3 years, 
68.4% of the primary grafts and half of the 
grafts used for retransplantation are still pro-
viding satisfactory function. The 3-year 
patient mortality in the trial has been·21.2%. 
Phase II (1981) 
The most important part of the study 
encompassed the calendar year 1981, during 
which, at the University of Pittsburgh, 65 
cadaveric kidneys were transplanted to 64 
patients (Table 3). Thirty-eight of the 
patients were primary graft recipients under 
cyclosporine-steroid therapy. The other 26 
were undergoing retransplantation after one 
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Table 1. Three Phases of Cyclosporine-Steroid Cadaveric Kidney Trials 
Primary 
Phase Yearls, Location Transplantations Retransplantations 
12/1979-9/1980 Colorado 57 10 (9 patients) 
II 1981 Pittsburgh 38* 27 (26 patients) 
III 1982 Pittsburgh 96 22 
*Part of randomized trial against azathioprine-steroid therapy, which was used for 32 patients. 
or more kidneys had been rejected or lost for 
other reasons at some time in the past. At the 
same time, 32 patients who were part of a 
randomized trial had primary cadaveric 
transplantation under azathioprine and pred-
nisone, 
By this time a firm idea had evolved about 
the expectations after cadaveric transplanta-
tion under cyclosporine-steroid therapy and 
the appropriate therapeutic response under 
varying postoperative conditions.4 The stan-
dard postoperative recipe in adults receiving 
17.5 mg/kg/day cyclosporine was a 5-day 
burst of prednisone, beginning with 200 mg/ 
day, and with daily decrements of 40 mg until, 
after 6 days, a maintenance dose of 20 mg/ 
day had been reached. An untroubled conva-
lescence without rejection was called a Class I 
course. Patients who developed what was 
thought to be a rejection in spite of this 
treatment were given a second 5-day steroid 
burst, often with a bolus or two of steroids in 
addition. Secondary deterioration of renal 
function characterized a Class II recovery. In 
such patients, chronic high-dose steroid ther-
apy was not permitted. An upper limit of 30 
mg/day prednisone as a maintenance dose 
was placed on adults. If recovery did not 
follow with this conservative approach, it was 
assumed that cyclosporine nephrotoxicity was 
responsible, and the dose of this drug was 
reduced. 
A third kind of postoperative evolution, 
termed Class III, was in patients who either 
had no postoperative urine output at all or 
whose initial urine excretion was minima1.4 
Such recipients were treated with the same 
5-day burst of steroids as patients with a 
perfectly benign recovery, and no other 
adjustments were made for about 2 weeks. 
Then, manipulation of either the cyclosporine 
or steroid doses was considered. 
Only about one-third of the patients had a 
Class I recovery. The majority had some 
secondary deterioration of function after rea-
sonable initial performance by the graft and 
were said to have passed through a Class II 
convalescence. A few patients had complete 
anuria from the outset (Class III). The inci-
dence of sustained good graft function was 
much higher in the patients undergoing pri-
mary transplantation than in those who were 
receiving retransplants.4 In the latter immu-
nologically high-risk recipients, there was a 
high incidence of widely reacting preformed 
antibodies. 
Primary cadaveric recipients. By the end 
of the first postoperative year, two of the 
patients in the randomized trial (2.9%) had 
died, one each from the control and study 
groups. The I-year survival of the cadaveric 
grafts under cyc1osporine-steroid therapy was 
89.5%, and under conventional immunosup-
pression it was 50%. This divergence in results 
Table 2. Colorado Cyclosporine Trial (1979-1980) 
Survival 10 Retransplantations 
Months (66 patients' 57 First Grafts (9 patients) 
0 66 57 10 
6 58 (87.9%) 48 (84.2%) 6 (60%) 
12 57 (86.4%) 45 (79.0%) 6 (60%) 
18 57 (86.4%) 44 (77.2%) 6(60%) 
24 56 (84.8%) 43 (75.4%) 6 (60%) 
32-42 52 (78.8%) 39 (68.4%) 5 (50%) 
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Table 3. Primary Cadaveric Transplantation. 
Pittsburgh Cyclosporine Trial (1981) 
Graft Survival Graft Survival 
Survival of (Cyclosporine + (Azathioprine + 
Months Patients· Steroids) Steroids 
0 70 38 32 
6 69 (98.6%) 34 (89.5%) 22 (68.8%) 
12 68 (97.1%) 34 (89.5%) 16 (50%) 
17-27 67 (95.7%) 33 (86.8%) 15 (47%) 
*Two deaths in cyclosporine group from: myocardial 
infarction (3 weeks) and mesenteric infarction (17 months); 
one death in azathioprine group from gastrointestinal hemor-
rhage (7 months). 
continued through a II/2-year period up to the 
present time, now with follow-ups of 17 to 27 
months. A detailed analysis of the results has 
been published.s 
The trial was brought to an end in Decem-
ber 1981. Toward the end of the trial, there 
was a genuine revolt among the patient popu-
lation as well as among the personnel on the 
transplantation ward who realized the disad-
vantaged position in which the control 
patients being treated with azathioprine and 
prednisone were placed. 
Cadaveric retransplant at ion. Mean-
while, in 1981, 27 cadaveric retransplanta-
tions were carried out in 26 patients. The large 
number of retransplantations was compiled 
because the staff and patients both came to 
realize that patients undergoing retransplan-
tation were not being randomized and thus 
could count on being treated with cyclospo-
rine. In this group (Table 4), the I-year graft 
Table 4. Cadaveric Graft Survival After 
Retransplantation in 1981 (Cyclosporine Series) 
22 Retransplants 
27 Retransplant in 22 Pabents 
in 26 Patients (Azathioprine + 
Months (Cyclosporine + Steroids) Steroids)· 
3 23 (85.2%) 15 (68.2%) 
6 21 (77.8%) 13 (59.1%) 
12 21 (77.8%) 8 (36.4%) 
18 19 (70.4%) 7 (31.8%) 
20-30 18 (66.7%)t 6 (27.3%) 
* Historical controls. 
tOf the three late graft losses, two were from chronic 
rejection after 12 and 13 months; the third was from death 
(ruptured aneurysm) after 18Y, months. The death was the 
only one in the series. 
Table 5. Cadaveric Cases in 1982 
(Cyclosporine + Steroids)· 
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*Follow-ups 4)1..-16)1.. months. 
77 
20 
survival was 78%; now, with a median follow-
up of 2 years, 67% of these grafts are still 
functioning. The results were more than twice 
as good as in a group of historical controls 
compiled over the preceding 3 years. The 
I-year mortality in this difficult group of 
patients was zero, although a patient died 
181/ 2 months after transplantation of a rup-
tured abdominal aneurysm. 
Phase III (1982) 
The results obtained m 1982 have been 
generally confirmatory of the earlier ones. 
Ninety-six primary cadaveric transplants 
were carried out in 1982; the graft survival 
after 5 to 161/ 2 months is 78% (Table 5). The 
lower graft survival during this most recent 
year was due mainly to an almost 10% patient 
mortality, which for the most part was caused 
by myocardial infarctions and other complica-
tions of vascular disease. A loosening of the 
criteria of case selection was thought to have 
been responsible for the increased mortality. 
In contrast, 22 patients underwent retrans-
plantation in 1982, with a present graft sur-
vival greater than 90% and with a 5% patient 
mortality (Table 5), 
DISCUSSION 
The way in which cyclosporine-steroid ther-
apy will influence practices in renal transplan-
tation is still speculative, but the new horizons 
opened thereby will be broad. Our own use of 
the drug now extends 31/ 2 years, and beyond 
that there are a significant number of patients 
being followed by Caine et al. of England.6 
The possibility of treating patients for years 
with cyclosporine has been thoroughly demon-
strated, although the ultimate maintenance 
doses of the drug reached in order to avoid 
nephrotoxicity have sometimes been surpris-
ingly small. 
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The specter of lymphoma production with 
cyclosporine has been all but replaced with a 
comfortable understanding that most of the 
lesions grouped under this frightening classifi-
cation are not true lymphomas as Rosenthal 
and others describe. The term pseudo lym-
phoma used by Iwatsuki et a1. for such Iym-
phoproliferative lesions may be an appropri-
ate one.7 
The good results obtained both in Denver 
and in Pittsburgh were without the kind of 
systematic recipient transfusion that has 
become so popular among nephrologists and 
without the kind of good tissue matching that 
at one time was envisioned as an important 
condition for successful cadaveric transplan-
tation. The ways in which an of the observa-
tions made over the last several years could 
alter the so-called strategy of transplantation 
has been speculated upon elsewhere.s Because 
of the outstanding results obtained with 
cadaveric transplantation, the use of living 
donors has lost much of its attractiveness. The 
importance of tissue matching at the A, B, 
STARZL ET AL. 
and D loci will be reduced. Since cyclosporine 
cannot prevent hyperacute rejection, the 
importance of accurately identifying pre-
formed antidonor T-warm antibodies will be 
increased. As a corollary, it will become 
increasingly important to avoid sensitization 
of potential kidney recipients by deliberate 
transfusion. Because it has been so much 
easier to treat diabetics with the low steroid 
doses that are needed with cyclosporine, these 
patients have become more attractive candi-
dates for cadaveric organs. Other patients of 
marginal candidacy will be more freely admit-
ted to transplant waiting lists. The fact that 
the organ supply will become critical is quite 
obvious. 
SUMMARY 
The immunosuppression provided with 
cycIosporine and steroids has greatly in-
creased the effectiveness of cadaveric kidney 
transplantation both in patients receiving 
their first kidneys and in those undergoing 
retransplantation. 
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